CANINE PARVOVIRUS TYPE 2c ISOLATES AND METHODS OF USE
AssigneeIntervet Inc.
InventorsTerri L. Wasmoen, Nallakannu P. Lakshmanan, Kenneth A. Stachura, Jessica A. Moore, Thomas Clinton Gore
Life of this patent
Estimating the term…
Abstract
The present invention discloses an attenuated canine parvovirus. In addition, the present invention discloses isolated and/or recombinant canine parvovirus capsid proteins and the nucleic acids that encode the canine parvovirus capsid proteins. The present invention further discloses immunogenic compositions and/or vaccines comprising the attenuated canine parvovirus isolates, corresponding capsid proteins, and/or recombinant vectors which express nucleic acids that encode the canine parvovirus capsid proteins.
Claims20
An isolated attenuated canine parvovirus (CPV) isolate comprising a genome that encodes a capsid protein comprising an amino acid sequence that comprises 98% or greater identity with the amino acid sequence of SEQ ID NO:
- 2;
- wherein the amino acid sequence of the capsid protein comprises a glutamic acid residue at position 426 (E426), and lysine residues at amino acid positions 93 (K93), 219 (K219), and 377 (K377).
An isolated attenuated canine parvovirus (CPV) isolate comprising the identifying characteristics of ATCC accession No. PTA-13492.
A polypeptide that comprises an amino acid sequence that comprises 98% or greater identity with the amino acid sequence of SEQ ID NO:
- 2 or an antigenic fragment thereof;
- wherein the amino acid sequence of the polypeptide or that of the antigenic fragment thereof comprises a glutamic acid residue at position 426 (E426) and an amino acid residue selected from the group consisting of a lysine residue at position 93 (K93), a lysine residue at position 219 (K219), a lysine residue at position 377 (K377), an isoleucine residue at position 555 (I555), a serine residue at position 300 (S300), an alanine residue at position 301 (A301), or any combination thereof;
- and wherein said polypeptide or the antigenic fragment thereof is in a form selected from the group consisting of isolated, recombinant, or both isolated and recombinant.
Dependencies are inferred from the claim text.